SequelSEC

USANA HEALTH SCIENCES INC USNA

Medicinal Chemicals & Botanical Products · CIK 0000896264 · Fiscal year ends 0103

Revenue
$925.26M
Fiscal year ended 2026-01-03
Operating income
$37.43M
Fiscal year ended 2026-01-03
Free cash flow
$8.53M
Fiscal year ended 2026-01-03

USANA HEALTH SCIENCES INC (USNA) reported revenue of $925.26M and net income of $10.76M for the fiscal year ended 2026-01-03. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from USANA HEALTH SCIENCES INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Medicinal Chemicals & Botanical Products.

Income

USANA HEALTH SCIENCES INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-01-032024-12-282023-12-302022-12-312022-01-012021-01-022019-12-282018-12-292017-12-302016-12-31
Revenue$925.26M$854.50M$921.01M$998.60M$1.19B$1.13B$1.06B$1.19B$1.05B$1.01B
Cost of revenue$200.85M$161.21M$176.69M$193.89M$217.90M$209.11M$187.50M$200.71M$179.40M$180.19M
Gross profit$724.40M$693.29M$744.32M$804.71M$968.57M$925.53M$873.40M$988.54M$867.86M$825.89M
Operating income$37.43M$66.32M$93.07M$107.61M$170.19M$176.49M$146.19M$188.35M$132.50M$138.62M
Net income$10.76M$42.03M$63.79M$69.35M$116.50M$124.66M$100.53M$126.22M$62.54M$100.04M
Research & development$10.69M$11.57M$11.45M$11.56M$11.11M$10.63M$10.26M$10.24M$8.95M$8.84M
Weighted-average diluted sharesshares 18.57Mshares 19.16Mshares 19.34Mshares 19.31Mshares 20.34Mshares 21.26Mshares 22.82Mshares 24.64Mshares 24.71Mshares 25.05M
Pretax income$41.53M$76.35M$102.45M$108.62M$170.64M$177.95M$150.50M$191.51M$134.64M$138.55M
Income tax expense$30.05M$34.29M$38.66M$39.27M$54.14M$53.28M$49.97M$65.29M$72.10M$38.51M
Diluted EPS$0.58$2.19$3.30$3.59$5.73$5.86$4.41$5.12$2.53$3.99
Selling, general & administrative$337.37M$263.27M$256.99M$262.30M$279.11M$261.19M$267.73M$275.06M$265.09M$234.19M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

USANA HEALTH SCIENCES INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-01-032024-12-282023-12-302022-12-312022-01-012021-01-022019-12-282018-12-292017-12-302016-12-31
Cash & equivalents$158.38M$181.77M$330.42M$288.42M$239.83M$311.92M$234.83M$214.33M$247.13M$175.77M
Total assets$742.92M$748.19M$632.76M$596.55M$577.74M$640.89M$516.93M$554.46M$519.27M$470.64M
Current assets$288.40M$279.19M$417.75M$384.38M$365.12M$425.29M$329.28M$392.34M$340.16M$277.86M
Total liabilities$156.64M$161.86M$135.56MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current liabilities$128.56M$139.62M$118.84M$143.83M$160.79M$168.07M$136.10M$148.69M$141.18M$138.49M
Total equity incl. NCI$533.10M$532.11M$497.20M$434.47M$395.12M$441.65M$351.71M$391.15M$363.21M$325.29M
Temporary (mezzanine) equity$53.17M$54.22M$0UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$102.61M$69.74M$61.45M$67.09M$98.32M$90.22M$68.90M$81.95M$62.92M$64.81M
Accounts receivable$4.28MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Goodwill$137.96M$144.17M$17.10M$17.37M$17.67M$17.37M$16.64M$16.82M$17.42M$16.72M
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$17.26M$11.98M$10.07M$11.05M$13.51M$18.20M$12.52M$9.95M$11.79M$9.04M

Cash flow

USANA HEALTH SCIENCES INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-01-032024-12-282023-12-302022-12-312022-01-012021-01-022019-12-282018-12-292017-12-302016-12-31
Operating cash flow$22.35M$60.99M$70.64M$103.90M$121.23M$160.40M$126.73M$152.12M$123.77M$136.89M
Capital expenditures$13.82M$10.07M$14.49M$10.40M$12.76M$15.09M$16.57M$11.43M$13.22M$32.70M
Investing cash flow-$10.12M-$213.09M-$11.98M-$12.37M-$14.19M-$33.96M$47.49M-$69.00M-$12.90M-$31.88M
Financing cash flow-$40.60M$9.55M-$14.24M-$30.09M-$181.41M-$59.44M-$152.05M-$105.28M-$50.32M-$64.86M
Net change in cash-$23.27M-$148.74M$41.93M$47.67M-$72.28M$78.25M$20.45M-$33.30M$71.58M$32.22M
Stock-based compensation$13.83M$14.56M$14.60M$13.33M$14.30M$14.39M$15.54M$14.96M$15.48M$16.54M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchases$27.51M$9.44M$11.60M$25.38M$177.84M$57.03M$150.00M$105.38M$50.00M$64.61M
Depreciation & amortization$32.56M$14.54M$12.70M$13.39M$13.04M$13.75M$14.74M$16.84M$16.11M$13.48M

Derived

USANA HEALTH SCIENCES INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-01-032024-12-282023-12-302022-12-312022-01-012021-01-022019-12-282018-12-292017-12-302016-12-31
Free cash flow$8.53M$50.92M$56.15M$93.50M$108.46M$145.31M$110.16M$140.69M$110.55M$104.19M
Gross margin78.3%81.1%80.8%80.6%81.6%81.6%82.3%83.1%82.9%82.1%
Operating margin4.0%7.8%10.1%10.8%14.3%15.6%13.8%15.8%12.7%13.8%
FCF margin0.9%6.0%6.1%9.4%9.1%12.8%10.4%11.8%10.6%10.4%
SBC / revenue1.5%1.7%1.6%1.3%1.2%1.3%1.5%1.3%1.5%1.6%
Current ratio2.24x2.00x3.52x2.67x2.27x2.53x2.42x2.64x2.41x2.01x
Revenue YoY growth8.3%-7.2%-7.8%-15.8%4.6%7.0%-10.8%13.6%4.1%Unavailable
Net margin1.2%4.9%6.9%6.9%9.8%11.0%9.5%10.6%6.0%9.9%
R&D / revenue1.2%1.4%1.2%1.2%0.9%0.9%1.0%0.9%0.9%0.9%
CapEx / revenue1.5%1.2%1.6%1.0%1.1%1.3%1.6%1.0%1.3%3.3%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rate72.4%44.9%37.7%36.2%31.7%29.9%33.2%34.1%53.6%27.8%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open USNA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-16View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-06View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.